Cover Image
市場調查報告書

Letrozole的中國市場:2010年∼2019年

Investigation Report on China Letrozole Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 337516
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Letrozole的中國市場:2010年∼2019年 Investigation Report on China Letrozole Market, 2010-2019
出版日期: 2015年08月18日 內容資訊: 英文 20 Pages
簡介

目前每年有約120萬人乳癌發病,此外50萬名女性因乳癌而喪命。中國乳癌新患者數佔全球整體的12.2%。另外死亡數則佔9.6%。乳癌治療藥Letrozole的銷售額,自打入中國市場以來便急速擴大,2005年僅約2,000萬人民幣的銷售額,之後便以35.1%的年複合成長率(CAGR)擴大,到2014年達到3億人民幣的規模。

本報告提供中國的Letrozole的專利及核準情況,提供您銷售額·銷售量的變化與預測,價格趨勢,主要的製藥公司及其市場佔有率,競爭環境與其展望,還有主要製造商的簡介等資訊。

第1章 Letrozole的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Letrozole的市場簡介

  • 專利·核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國的Letrozole銷售情形

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的主要Letrozolemeka的市場佔有率

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國的Letrozole的劑型的相關調查

第6章 中國的醫院的Letrozole的標準價格

  • Jiangsu Hengrui Medicine Co., Ltd (商品名:Furui)
  • Novartis AG (Switzerland) (商品名:Femara)

第7章 中國市場中Letrozole的主要製藥公司

  • Jiangsu Hengrui Medicine Co., Ltd
  • Novartis AG (Switzerland)

第8章 中國的Letrozole的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1508299

Currently, breast cancer has become the first killer of women with new cases reaching about 1.2 million and 0.5 million women dying of it each year.

According to Breast Cancer in China which was published in 2014, the number of new cases and deaths in China respectively accounted for 12.2% and 9.6% of the world sum. And the growth rate of China doubled that of the world. According to the statistics, breast cancer with increasing incidence is the most common malignant cancer for Chinese women. And the average age at onset is 10-15 years younger than that in Europe and America. As the third generation of aromatase inhibitor developed by Novartis, letrozole entered United Kingdom first in 1996 and the US in 1997 before being widely used as the first-line drug for advanced breast cancer and as the second-line drug for breast cancer. At home, Jiangsu Hengrui Medicine Co., Ltd was approved to market letrozole under the trade name of Furui in 1999, followed by Femara of Novaris in 2003.

According to CRI's market survey, letrozole develops fast after entering China with sales value rising from about CNY 20 million in 2005 to over CNY 300 million in 2014 and CAGR during this period reaching 35.1%. As Femara of Novartis is priced two times higher than local products, its sales volume only accounted for less than 50% of the sum despite its market share of 73.62% in 2014. The gradual decrease in Novatis's market share, however, constitutes a great opportunity for local enterprises. Currently, there are only two kinds of letrozole available in the Chinese market, indicating a high entry barrier and a large market.

Studies have shown the uniqueness of breast cancer in China: special fertility pattern due to family planning as well as modern lifestyle like high-fat diet and little exercise increases the risk of breast cancer.

It is expected that letrozole will enjoy a vast demand in China.

Readers can get at least the following information through this report:

  • market size of letrozole in China
  • competitive landscape of letrozole market in China
  • price of letrozole made by different enterprises in China
  • market outlook of letrozole in China

The author suggests the following groups of people purchase this report:

  • manufacturers of antitumor agents
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Letrozole

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Letrozole in China

  • 2.1. Patent and Approval Information of Letrozole in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. sSurvey on Letrozole Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Letrozole Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Letrozole in China, 2010-2014

6. Reference Price of Letrozole in Chinese Hospitals in 2014

  • 6.1. Jiangsu Hengrui Medicine Co., Ltd (Trade Name: Furui)
  • 6.2. Novartis AG (Switzerland) (Trade Name: Femara)

7. Major Manufacturers of Letrozole in Chinese Market, 2010-2014

  • 7.1. Jiangsu Hengrui Medicine Co., Ltd
  • 7.2. Novartis AG (Switzerland)

8. Market Outlook of Letrozole in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent of Letrozole in China
  • Chart Approval Information of Letrozole in China
  • Chart Letrozole Sales in China
  • Chart Sales Value of Letrozole in China, 2010-2014
  • Chart Sales Value of Letrozole in Some Regions in China, 2010-2014
  • Chart Sales Volume of Letrozole in China, 2010-2014
  • Chart Sales Volume of Letrozole in Some Regions in China, 2010-2014
  • Chart Market Share of TOP2 Letrozole Manufacturers for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Letrozole Made by Novartis (Switzerland) in China, 2010-2014
  • Chart Sales Value and Market Share of Letrozole Made by Jiangsu Hengrui in China, 2010-2014
  • Chart Price of Letrozole Made by Jiangsu Hengrui Medicine Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Letrozole Made by Novartis AG (Switzerland) in Some Chinese Cities in 2014
Back to Top